Board of Directors

James F. Buck

President & CEO

Daniel Pelak

Lead Director
PelakDan has served on Mardil’s Board since 2009 and is Senior Advisor at Welsh, Carson, Anderson & Stowe one of the largest private equity firms in the US and has been associated with the firm since 2008. He has over twenty-five years of experience as a senior executive in the medical technology industry, compiling a successful track record in growing young companies and corporate operating divisions. Mr. Pelak was previously the Chief Executive Officer at InnerPulse, a privately held, early-stage cardiac medical device company. Before joining InnerPulse, he was the Chief Executive Officer of Closure Medical Corporation, a publically traded global leader in the development and manufacture of biomaterial-based medical adhesives, until its acquisition by Johnson & Johnson in 2005. He began his industry career at Medtronic, Inc., where he spent more than two decades. His executive assignments there included Vice President of US marketing, and later in his career, the world wide responsibility for three different operating divisions as the Vice President and General Manager. He currently is the Chairman of the Board at K2M, Inc., and Chairman of the Board at Valeritas, Inc., additionally he serves on the board of directors of Vertos Medical, Inc., and Spectranetics Inc. Mr. Pelak is a graduate of Penn State University.

Ramesh Alur

Director
Ramesh is a General Partner at Ventureast Fund Advisors India and has been on Mardil’s Board since 2007. He focuses on Life Science, Healthcare, and Clean Environment investments at the firm. He has been with Ventureast for over 15 years, and was part of the APIDC team prior to its partnership with Ventureast where he served as General Partner of APIDC Fund and Biotechnology Venture Fund. He has worked closely with over 50 early to growth-stage companies in pharmaceuticals, specialty chemicals, manufacturing, infrastructure services, healthcare, dairy products, and alternative fuels. He started his career in 1978 as a Chemical Engineer with Bhabha Atomic Research Center. He also worked as Scientific Officer at Reactor Research Center, Kalpakkam and served at Bakelite Hylam. He is a Director for 10 companies, which include portfolio companies as well as a group companies of Ventureast. He holds an M.B.A. in Marketing and Finance from the Indian Institute of Management, Bangalore and B.Tech. degree in Chemical Engineering from REC Warangal.

Andrew Betts

Director
BettsAndy Betts is a retired audit partner from Ernst & Young where he spent thirty seven years serving publicly and privately held companies in the manufacturing, technology, financial services and insurance industries.  Andy has extensive experience in Securities and Exchange Commission reporting and in working with mergers and acquisitions.  He served as Director of Audit for the Raleigh office managing staff resources and client assignments for a professional staff of over 100.  Andy also worked on a National task force to innovate audit services to clients through technology and other audit tools.  He currently serves as a consultant on accounting matters and works part time as an audit director for BDO, USA in Raleigh.

Andy is on the board of Builders Mutual Insurance Company where he serves on the audit and governance committees.  He also is on the board of Athene Annuity and Life Assurance Company where he serves on the audit committee.  He serves on a number of local community and civic organizations and is currently board chair of StepUp Ministry.

Andy is a graduate of the University of North Carolina at Chapel Hill and the Executive Program of the Kellogg Graduate School at Northwestern University. He is a Certified Public Accountant, a member of the American Institute of CPAs and the NC Association of CPAs, a Fellow of the Life Management Institute and a Chartered Life Underwriter.

Marshall S. Stanton, MD

Director
StantonDr. Stanton joined Mardil’s Board in 2012 and is Vice President and General Manager of the Implantable Defibrillator business within Medtronic’s Cardiac Rhythm Disease Management (CRDM) business. Marshall has over 25 years of experience in cardiac rhythm management including 15 years at Medtronic and 10 years as a staff cardiologist at Mayo Clinic.

Prior to his current role, Dr. Stanton was Vice President for Clinical Research for Medtronic’s Cardiac and Vascular Group of businesses. Recently, Dr. Stanton was Vice President and General Manager for the Medtronic Japan CRDM business from May 2005 through June 2007 where he had responsibility for all aspects of the CRDM and PhysioControl businesses in Japan. Dr. Stanton had been the Medical Director for the CRDM business since joining Medtronic in 1998 until 2005. In this position, Dr. Stanton focused on the electrophysiology market worldwide, bringing healthcare expertise to product plans, quality, and education. This role also included collaborating with government relations, public relations, and investor relations. Dr. Stanton also held the position of Vice President, Advanced Product Development from 2002-2005. This entailed leading a large product development team for pacemakers and defibrillators.

Marshall served for three years as a member of the Center for Medicare and Medicaid Services’ (CMS) Medicare Coverage Advisory Committee.

Before joining Medtronic, Dr. Stanton was Associate Professor of Medicine and Director of the Cardiovascular Training Program at the Mayo Graduate School of Medicine, Mayo Clinic, Rochester, Minnesota, where he was on staff from 1989 – 1998. Prior to that, he was a fellow in cardiology and electrophysiology at Indiana University School of Medicine and a Mayo Scholar. He received his Doctor of Medicine degree from the Medical College of Virginia in 1982, having received a Bachelor of Arts from the University of Pennsylvania in 1978.

Naser Jaafar

Director
JaafarNaser is the Executive Vice President of Strategic Initiatives and Funding at Agensi Inovasi Malaysia (AIM). His team is responsible for creating wealth through innovation for the country via three delivery channels specifically, open bidding of new technology sourced from local universities and Public Research Institutes, direct equity investment by AIM and also matching of Entrepreneurs and Promoters. Naser also heads the team at AIM, which is the joint secretariat with Ministry of Science, Technology and Innovation for the Investment Committee of Public Funds (ICPF). This team is responsible for the evaluation, development of KPIs and Performance Management of all the public funds for Research, Development and Commercialization (R,D&C) in Malaysia. Prior to joining AIM, Naser was with Bank of America Merrill Lynch Malaysia for 22 years, of which the last 9 years as the Chief Executive Officer. Naser has served various positions at the Bank in Malaysia, Singapore and Jakarta. Naser received his Masters of Business Administration from North Texas State University, USA in 1987.

Warren S. Watson

Director
WatsonMr. Watson is a medical device executive with over 35 years of med tech experience. Mr. Watson’s career began with Medtronic, Inc. where he served in capacities of increasing responsibility over greater than 30 year tenure. Mr. Watson focused in the Cardiac Rhythm Management, Cardiac Ablation, Heart Failure and Cardiology fields including positions in technical management, clinical and regulatory responsibilities, business development, strategic and marketing responsibilities, and general management. Mr. Watson served as VP of Research and Development for the Cardiac Rhythm Management business for over 8 years and was Chair of the Medtronic Corporate Research and Development Council. Mr. Watson retired from Medtronic with 33 years of service to the Company.

Following his retirement from Medtronic, Mr. Watson has served on multiple medical device Boards including Cameron Health where he served as the Executive Chair of the Board of Directors prior to Cameron Health being acquired by Boston Scientific, Inc. in June, 2012. Mr. Watson also currently serves on the Board for Sunshine Heart, Inc., a medical device company with an implantable non-blood contact heart assist therapy for the treatment of moderate to severe heart failure. He also serves on five other medtech and philanthropic Boards.

Mr. Watson is a graduate of the University of Minnesota with undergraduate and graduate degrees in Electrical Engineering. He resides in New Brighton, MN.